Topical Corticosteroids Autosubstitutions:

Based on an evaluation of the current topical corticosteroids on the Formulary, the Pharmacy and Therapeutics Committee agreed to establish a set of autosubstitutions based on potency and commonly prescribed products. Listed below are the approved formulary products and the corresponding potencies that will be used for substitution.

High Potency	Triamcinolone acetonide	Kenalog®, Aristocort®	Cream, Ointment	0.5%
Medium Potency	Triamcinolone acetonide	Kenalog®, Aristocort®	Cream, Ointment	0.1%
Low Potency	Hydrocortisone	Generic	Cream, Ointment	1%

Latex Sensitivity/Allergy Protocol Revised:

The Latex Allergy Protocol has been revised after a comprehensive review of the handling and preparation of IV drug products for administration to patients with latex allergies. The significant changes include:

• eliminating the need to filter

• do not remove rubber stoppers and metal casings

• utilize one-stick method for entering a vial (may use two sticks if reconstituting a dry powder).

Formulary Review of Contrast Media:

In a move to provide a comprehensive formulary listing of all drug products and recognizing that contrast media are approved by the FDA as drugs, the P&T Committee will be formally reviewing these agents and including them on the SFMC Formulary.

The first drug reviewed and approved to the Formulary was gadoteridol (ProHance®), which is used as a gadolinium-containing contrast agent.

Formulary Deletions and Autosubstitutions:

Drug Deletion	Reason	Autosubstitution
Cimetidine (Tagamet®	low use and lack of evidence for treating urticaria or anaphylaxis	Famotidine (Pepcid®)
Rubella, Measles, and Mumps Vaccines	Use of combination vaccines such as MMR is recommended by CDC	Measles, Mumps, Rubella (MMR®)
Procainamide sustained-release (Procanbid®)	Product no longer manufactured	No Autosubstitution. Regular-release